SG161259A1 - Method for treatment of constipation-predominant irritable bowel syndrome - Google Patents

Method for treatment of constipation-predominant irritable bowel syndrome

Info

Publication number
SG161259A1
SG161259A1 SG201002504-7A SG2010025047A SG161259A1 SG 161259 A1 SG161259 A1 SG 161259A1 SG 2010025047 A SG2010025047 A SG 2010025047A SG 161259 A1 SG161259 A1 SG 161259A1
Authority
SG
Singapore
Prior art keywords
constipation
bowel syndrome
irritable bowel
treatment
ibs
Prior art date
Application number
SG201002504-7A
Other languages
English (en)
Inventor
Barry Quart
David Rosenbaum
Original Assignee
Napo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Napo Pharmaceuticals Inc filed Critical Napo Pharmaceuticals Inc
Publication of SG161259A1 publication Critical patent/SG161259A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Agronomy & Crop Science (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG201002504-7A 2006-05-01 2007-04-30 Method for treatment of constipation-predominant irritable bowel syndrome SG161259A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79707606P 2006-05-01 2006-05-01

Publications (1)

Publication Number Publication Date
SG161259A1 true SG161259A1 (en) 2010-05-27

Family

ID=38668465

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2013075551A SG195538A1 (en) 2006-05-01 2007-04-30 Method for treatment of constipation-predominant irritable bowel syndrome
SG201002504-7A SG161259A1 (en) 2006-05-01 2007-04-30 Method for treatment of constipation-predominant irritable bowel syndrome

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2013075551A SG195538A1 (en) 2006-05-01 2007-04-30 Method for treatment of constipation-predominant irritable bowel syndrome

Country Status (19)

Country Link
US (3) US7556831B2 (es)
EP (2) EP2015639A4 (es)
JP (2) JP2009535419A (es)
KR (2) KR20090009292A (es)
AU (1) AU2007248182B2 (es)
CA (1) CA2650022C (es)
CY (1) CY1113723T1 (es)
DK (1) DK2241318T3 (es)
ES (1) ES2401366T3 (es)
HK (1) HK1143541A1 (es)
HR (1) HRP20130203T1 (es)
MX (1) MX2008013768A (es)
NZ (3) NZ609280A (es)
PL (1) PL2241318T3 (es)
PT (1) PT2241318E (es)
RS (1) RS52678B (es)
SG (2) SG195538A1 (es)
SI (1) SI2241318T1 (es)
WO (1) WO2007130892A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2401366T3 (es) 2006-05-01 2013-04-19 Napo Pharmaceuticals, Inc. Método para tratamiento de síndrome del intestino irritable con estreñimiento predominante
EP2061327B1 (en) * 2006-05-01 2016-10-05 Napo Pharmaceuticals, Inc. Compositions for treating or preventing inflammatory bowel disease
US20070254050A1 (en) * 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
US8436051B2 (en) 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US7541384B2 (en) 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US8734867B2 (en) * 2007-12-28 2014-05-27 Liveleaf, Inc. Antibacterial having an extract of pomegranate combined with hydrogen peroxide
WO2009131947A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising pyridazine derivatives
US20090264433A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazine Derivatives
US8236838B2 (en) * 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
WO2009131957A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
JP2012503005A (ja) * 2008-09-19 2012-02-02 インスティテュート フォア ワンワールド ヘルス イミダゾール誘導体およびトリアゾール誘導体を含む、化合物、組成物ならびに方法。
JP4565219B2 (ja) * 2008-12-26 2010-10-20 アサヒビール株式会社 ポリフェノール含有顆粒またはポリフェノール含有チュアブル錠剤およびその製造方法
SG173905A1 (en) 2009-03-04 2011-09-29 Metaactiv Inc Method and material for site activated complexing of biologic molecules
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
US20120202876A1 (en) * 2009-10-06 2012-08-09 Napo Pharmaceuticals, Inc. Methods of treating diseases with proanthocyanidin oligomers such as crofelemer
AU2011320155B2 (en) * 2010-10-31 2016-02-25 Napo Pharmaceuticals, Inc. Methods and compositions for treating HIV-associated diarrhea
US8722040B2 (en) 2011-06-24 2014-05-13 Liveleaf, Inc. Site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites
US20120329736A1 (en) * 2011-06-24 2012-12-27 Huang Alexander L Treatment for gastrointestinal disorders using a selective, site-activated binding system
US9192635B2 (en) 2011-06-24 2015-11-24 Liveleaf, Inc. Method of treating damaged mucosal or gastrointestinal tissue by administering a composition comprising a mixture of pomegranate and green tea extracts and releasably bound hydrogen peroxide
MX369122B (es) 2012-11-21 2019-10-30 Kbs Res Llc Suplementos herbales y métodos para utilizar los mismos.
US8716351B1 (en) 2012-12-23 2014-05-06 Liveleaf, Inc. Methods of treating gastrointestinal spasms
US9510880B2 (en) 2013-08-13 2016-12-06 Zimmer, Inc. Polyaxial locking mechanism
US20170119834A1 (en) * 2014-05-29 2017-05-04 Jaguar Animal Health, Inc. Methods of Treating Diarrhea in Adult Non-Human Animals
US10282369B2 (en) * 2017-03-08 2019-05-07 Centri Technology, Inc. Fast indexing and searching of encoded documents
JOP20190276A1 (ar) 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج إسهال الحمض الصفراوي، والإسهال المرتبط باستئصال الأمعاء الدقيقة أو إزالة المرارة، ومتلازمة الأمعاء القصيرة
JOP20190275A1 (ar) 2017-05-31 2019-11-27 Napo Pharmaceuticals Inc طرق وتركيبات لعلاج اضطراب إسهال خِلقي
AU2018253466B2 (en) * 2017-07-17 2019-03-28 smartDNA Pty Ltd Method of diagnosing a dysbiosis

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE446940B (sv) 1983-02-16 1986-10-20 Carl Axel Virdalm Medel for bekempande av sjukdomstillstand i matsmeltningsapparaten innehallande skal eller ytterdelar av ber eller frukter
US4698360B1 (en) 1985-04-09 1997-11-04 D Investigations Pharmacologiq Plant extract with a proanthocyanidins content as therapeutic agent having radical scavenger effect and use thereof
DE3564370D1 (en) 1985-08-30 1988-09-22 Nestle Sa Dietetic product with depurating and antidiarrheal activity and process for its preparation
US5211944A (en) * 1990-10-12 1993-05-18 Shaman Pharmaceuticals, Inc. Proanthocyanidin polymers having antiviral activity and methods of obtaining same
SI9011933A (sl) 1990-10-15 1998-06-30 TANIN SEVNICA Kemična industrija p.o. Kostanjev taninski ekstrakt, postopek za njegovo pridobivanje in njegova uporaba
US5234922A (en) 1992-09-28 1993-08-10 University Of Iowa Research Foundation Use of sulfonylureas and other potassium channel regulators to treat secretory diarrhea
DK0935417T3 (da) 1996-10-16 2009-08-10 Napo Pharmaceuticals Inc Enteroformuleringer af proanthocyanidin-polymer-sammensætninger mod diarré
AU6967198A (en) 1997-04-10 1998-10-30 Eli Lilly And Company Diarylsulfonylureas for use in treating secretory diarrhea
CN1215561A (zh) * 1997-10-27 1999-05-05 邢文海 保健茶
US7767203B2 (en) * 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
WO2000047062A2 (en) 1999-02-01 2000-08-17 Shaman Pharmaceuticals, Inc. Enteric formulations of proanthocyanidin polymer dietary supplements and methods for preparing same
CN1159054C (zh) 2002-01-22 2004-07-28 随志化 通腑止泻剂
US20040063695A1 (en) 2002-09-30 2004-04-01 Alan Verkman Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
US7235573B2 (en) 2002-09-30 2007-06-26 The Regents Of The University Of California Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors
US7208183B2 (en) 2002-10-05 2007-04-24 Bobrowski Paul J Methods and preparations of the latex from the croton species
US7303772B2 (en) * 2005-11-10 2007-12-04 Olalde Rangel Jose Angel Synergistic phytoceutical compositions
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
ES2401366T3 (es) 2006-05-01 2013-04-19 Napo Pharmaceuticals, Inc. Método para tratamiento de síndrome del intestino irritable con estreñimiento predominante
EP2061327B1 (en) 2006-05-01 2016-10-05 Napo Pharmaceuticals, Inc. Compositions for treating or preventing inflammatory bowel disease
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US20120202876A1 (en) 2009-10-06 2012-08-09 Napo Pharmaceuticals, Inc. Methods of treating diseases with proanthocyanidin oligomers such as crofelemer
AU2011320155B2 (en) 2010-10-31 2016-02-25 Napo Pharmaceuticals, Inc. Methods and compositions for treating HIV-associated diarrhea
EP2928560A4 (en) 2012-12-07 2016-06-01 Salix Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF HIV-ASSOCIATED DIARRHEA

Also Published As

Publication number Publication date
WO2007130892A2 (en) 2007-11-15
KR20090009292A (ko) 2009-01-22
EP2015639A2 (en) 2009-01-21
KR20130067317A (ko) 2013-06-21
JP2014058548A (ja) 2014-04-03
US8067041B2 (en) 2011-11-29
RS52678B (en) 2013-06-28
NZ572049A (en) 2012-08-31
DK2241318T3 (da) 2013-01-21
EP2015639A4 (en) 2009-11-25
AU2007248182A1 (en) 2007-11-15
NZ609280A (en) 2014-09-26
CY1113723T1 (el) 2016-06-22
CA2650022A1 (en) 2007-11-15
EP2241318A1 (en) 2010-10-20
HRP20130203T1 (hr) 2013-04-30
PT2241318E (pt) 2013-03-18
WO2007130892A3 (en) 2008-10-30
HK1143541A1 (en) 2011-01-07
JP2009535419A (ja) 2009-10-01
US20090238901A1 (en) 2009-09-24
EP2241318B1 (en) 2012-12-19
PL2241318T3 (pl) 2013-05-31
ES2401366T3 (es) 2013-04-19
US7556831B2 (en) 2009-07-07
US20080031983A1 (en) 2008-02-07
SI2241318T1 (sl) 2013-04-30
AU2007248182B2 (en) 2013-05-23
NZ595679A (en) 2013-04-26
US20120128797A1 (en) 2012-05-24
SG195538A1 (en) 2013-12-30
US9138450B2 (en) 2015-09-22
CA2650022C (en) 2017-05-16
MX2008013768A (es) 2009-02-03

Similar Documents

Publication Publication Date Title
SG161259A1 (en) Method for treatment of constipation-predominant irritable bowel syndrome
WO2007130882A3 (en) Method for treatment of diarrhea-predominant irritable bowel syndrome
EA201070740A1 (ru) Способ лечения перелома кости антителами против склеростина
WO2005107771A3 (en) Composition comprising a survivin oligonucleotide and gemcitabine for the treatment of cancer
UA101309C2 (ru) Антагонисты активина-actrii и их применение для повышения уровня эритроцитов
MX2009006466A (es) Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
WO2011020061A3 (en) Compositions and methods of for treating bipolar disorder
WO2007100675A3 (en) Collagenase for treating cellulite
SG171648A1 (en) Use of dpp-iv inhibitors
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
MXPA05011886A (es) Metodos y composiciones para la prevencion y tratamiento de septicemia.
WO2006086693A3 (en) Medical devices
UA99094C2 (ru) Способ лечения пациента с системной красной волчанкой
WO2008054639A3 (en) Use of a catechin or polyphenol to treat ocular diseases and infection
WO2004091540A3 (en) Methods of treating pain and compositions for use therefor
WO2009103067A3 (en) Compositions and methods to treat asthma
MX2007008764A (es) Metodos para tratar capsulitis adhesiva.
WO2007120485A3 (en) Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
EA201001749A1 (ru) Способ лечения недифференцированного артрита
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
NO20081149L (no) Fremgangsmate for behandling av B-celle-maligniteter ved bruk av TACI-IG fusjonsmolekyl
TW200507840A (en) Method of treating multiple myeloma
WO2007100590A3 (en) Methods for treating cellulite
HK1102626A1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
MX2022010093A (es) Tafoxiparina para el tratamiento de la preeclampsia.